Reading room · November 7, 2026
Read the NAD+ compounding warning accurately
Understand what FDA’s warning says about sterile-compounding ingredients, what it does not establish about a provider and which questions it can help frame.
Educational and promotional content. CoreAge Rx is a featured commercial provider. No independent medical review or firsthand product testing is claimed.
Identify the subject of the warning
FDA has warned that food-grade NAD+ ingredients may be unsuitable for sterile compounding. It also describes reported adverse reactions after NAD+ injections that were consistent with endotoxin contamination. The subject is ingredient suitability and compounding practice. Keeping that scope visible helps you understand why preparation details matter without turning a general warning into a claim about every product carrying the NAD+ name.
Do not attach a finding to the wrong source
The warning is not evidence that CoreAge Rx or a pharmacy serving its patients supplied a contaminated preparation or violated a requirement. The checked product page does not establish those conclusions either. A useful question is which pharmacy would prepare the proposed product and how it addresses the information relevant to that preparation. An allegation about a named provider would require separate, specific evidence.
Bring the question to the actual care team
Ask the clinician to explain why the preparation is being considered and the pharmacy how to obtain its product-specific information and directions. Compounded drugs do not receive FDA premarket approval, so a listing should not be mistaken for an approval record. This workbook does not verify a dispensing process or supply handling instructions. It helps turn a broad concern into questions that the responsible professionals can answer.